We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 13, 2021

Longer-Term Outcomes With Single-Agent Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma

Cancer

 

Additional Info

Cancer
Longer Term Outcomes With Single-Agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma: 13-Month Follow-Up From the Pivotal DREAMM-2 Study
Cancer 2021 Jul 27;[EPub Ahead of Print], S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, N Callander, D Sborov, A Suvannasankha, K Weisel, PM Voorhees, L Womersley, J Baron, T Piontek, E Lewis, J Opalinska, I Gupta, AD Cohen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading